Therapeutic Advances in Immunotherapies for Hematological Malignancies

Following the success of immunotherapies such as chimeric antigen receptor transgenic T-cell (CAR-T) therapy, bispecific T-cell engager therapy, and immune checkpoint inhibitors in the treatment of hematologic malignancies, further studies are underway to improve the efficacy of these immunotherapie...

Descripción completa

Detalles Bibliográficos
Autores principales: Nogami, Ayako, Sasaki, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569660/
https://www.ncbi.nlm.nih.gov/pubmed/36232824
http://dx.doi.org/10.3390/ijms231911526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569660/
https://www.ncbi.nlm.nih.gov/pubmed/36232824
http://dx.doi.org/10.3390/ijms231911526

Ejemplares similares